Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients
- 1 August 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (8) , 1194-1203
Abstract
Background and objectives: High tacrolimus intrapatient variability has been associated with inferior graft outcomes in patients with kidney transplants. We studied baseline patterns of tacrolimus intrapatient variability in pediatric patients with kidney transplants and examined these patterns in relation to C1q-binding de novo donor-specific antibodies. Design, setting, participants, & measurements: All tacrolimus levels in participants who underwent kidney-only transplantation at a single pediatric center from 2004 to 2018 (with at least 12-month follow-up, followed until 2019) were analyzed to determine baseline variability. Intrapatient variability was defined using the coefficient of variation (SD/mean ×100%) of all samples in a 6-month moving window. Routine de novo donor-specific antibody measurements were available for a subgroup of patients transplanted in 2010–2018. Cox proportional hazards models using tacrolimus intrapatient variability as a time-varying variable were used to examine the association between intrapatient variability and graft outcomes. The primary outcome of interest was C1q-binding de novo donor-specific antibody formation. Results: Tacrolimus intrapatient variability developed a steady-state baseline of 30% at 10 months post-transplant in 426 patients with a combined 31,125 tacrolimus levels. Included in the outcomes study were 220 patients, of whom 51 developed C1q-binding de novo donor-specific antibodies. De novo donor-specific antibody formers had higher intrapatient variability, with a median of 38% (interquartile range, 28%–48%) compared with 28% (interquartile range, 20%–38%) for nondonor-specific antibody formers (P30%) had higher risk of de novo donor-specific antibody formation (hazard ratio, 5.35; 95% confidence interval, 2.45 to 11.68). Patients in the top quartile of tacrolimus intrapatient variability (coefficient of variation >41%) had the strongest association with C1q-binding de novo donor-specific antibody formation (hazard ratio, 11.81; 95% confidence interval, 4.76 to 29.27). Conclusions: High tacrolimus intrapatient variability was strongly associated with de novo donor-specific antibody formation.Keywords
Funding Information
- Stanford Maternal and Child Health Research Institute
- Stanford Transplant and Tissue Engineering Center of Excellence
- Landspitali University Hospital of Iceland
This publication has 36 references indexed in Scilit:
- Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody DevelopmentTransplantation, 2016
- Minimum mycophenolic acid levels are associated with donor‐specific antibody formationPediatric Transplantation, 2015
- Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomesPediatric Transplantation, 2014
- Age-Related Kidney Transplant OutcomesJAMA Internal Medicine, 2013
- Comprehensive Assessment and Standardization of Solid Phase Multiplex-Bead Arrays for the Detection of Antibodies to HLAAmerican Journal of Transplantation, 2013
- Age at Graft Loss after Pediatric Kidney TransplantationClinical Journal of the American Society of Nephrology, 2013
- Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first weekTransplant International, 2012
- Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal TransplantationTransplantation, 2011
- Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic reviewPediatric Transplantation, 2009
- Perceived barriers to adherence among adolescent renal transplant candidatesPediatric Transplantation, 2008